EUVIMEDEUVIMED entdecken
Crossref

Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells

Yaojin Zhu, Zhenqian Chen, Guoyuan Wu, Yuxin Fang, Yuhan Bao, Jiayi Zhu, Guoqiang Dong, Chunquan Sheng iD, Shipeng He

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yaojin Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine or School of Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, P. R. China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Cyclic Nucleotide Phosphodiesterases, Type 6, Nicotinamide Phosphoribosyltransferase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Rising-Star Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are a common type of oncogenic mutation, widely observed in various cancers. The trafficking chaperone PDE6D (or PDEδ) has been proposed as an alternative target for KRAS, which has led to the preclinical evaluation of PDEδ inhibitors for targeting KRAS mutant cancers. In this study, inspired by the synergistic effect between PDEδ and nicotinamide phosphoribosyl transferase (NAMPT), we report the discovery of the first PDEδ/NAMPT dual inhibitors, which may serve as an interesting starting point for targeting KRAS mutant pancreatic cancer cell lines (MiaPaca-2). Among these, a highly potent dual inhibitor (17d) was identified, exhibiting balanced and robust activity against PDEδ (KD = 0.410 nM) and NAMPT (IC50 = 2.21 nM). Notably, 17d demonstrated superior antitumor efficacy both in vitro and in vivo compared to either PDEδ or NAMPT inhibitors alone or in combination, highlighting the potential of PDEδ/NAMPT dual inhibitors in treating KRAS mutant pancreatic cancer cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Cyclic Nucleotide Phosphodiesterases, Type 6Nicotinamide PhosphoribosyltransferaseAntineoplastic AgentsCytokinesHumansAnimalsCell Line, TumorMutationMiceStructure-Activity RelationshipDrug DiscoveryMice, NudeXenograft Model Antitumor AssaysCell Proliferation

Substanzen

Proto-Oncogene Proteins p21(ras)Cyclic Nucleotide Phosphodiesterases, Type 6Nicotinamide PhosphoribosyltransferaseKRAS protein, humanAntineoplastic AgentsCytokinesnicotinamide phosphoribosyltransferase, human

Autor:innen und Institutionen

  • Institute of Translational Medicine or School of Medicine, Shanghai University, 99 Shangda Road, Shanghai 200444, P. R. China.
  • School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai 200433, P. R. China.

ORCID-Profile: Chunquan Sheng

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Rising-Star Program

Zitieren

APA

Zhu, Y., Chen, Z., Wu, G., Fang, Y., Bao, Y., Zhu, J., Dong, G., Sheng, C., & He, S. (2025). Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02636

Vancouver

Zhu Y, Chen Z, Wu G, Fang Y, Bao Y, Zhu J, et al. Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02636

BibTeX
@article{Zhu2025,
  author = {Zhu, Yaojin and Chen, Zhenqian and Wu, Guoyuan and Fang, Yuxin and Bao, Yuhan and Zhu, Jiayi and Dong, Guoqiang and Sheng, Chunquan and He, Shipeng},
  title = {Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02636}
}
Kostenlos starten →